Search Results - "Murren, John R."

Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501 by Horn, Leora, Dahlberg, Suzanne E, Sandler, Alan B, Dowlati, Afshin, Moore, Dennis F, Murren, John R, Schiller, Joan H

“…To investigate the efficacy and safety of bevacizumab plus cisplatin and etoposide in patients with extensive-stage disease, small-cell lung cancer (ED-SCLC)…”
Get full text

Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs by OTTERSON, Gregory A, VILLALONA-CALERO, Miguel A, KRAUT, Michael, MANI, Sridhar, MURREN, John R, SHARMA, Sunil, KRIS, Mark G, IMONDI, Anthony, GERBER, Mirjam, WHITE, Dorothy A, RATAIN, Mark J, SCHILLER, Joan H, SANDLER, Alan

“…Purpose: To evaluate the toxicity profile of inhalational doxorubicin in patients with malignant disease in the lung. Experimental Design: The OncoMyst Model…”
Get full text

Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer by Otterson, Gregory A, Villalona-Calero, Miguel A, Hicks, William, Pan, Xueliang, Ellerton, John A, Gettinger, Scott N, Murren, John R

“…We have shown the feasibility of administering inhaled doxorubicin to patients with cancer. This study evaluated inhaled doxorubicin combined with cisplatin…”
Get full text

Progress in the therapy of small cell lung cancer by Simon, Miklos, Argiris, Athanassios, Murren, John R.

“…Small cell lung cancer (SCLC) accounts for approximately 14% of all cases of lung cancer. Combination chemotherapy is the most effective treatment modality for…”
Get full text

Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer by Murren, John R., Andersen, Nicolaj, Psyrri, Diamondo, Brandt, Deborah, Nadkarni, Rajani, Rose, Michal, Parisot, Nicole, Rosenfield, Arthur T., Pizzorno, Giuseppe, Zelterman, Daniel

“…Purpose: We conducted a phase II study to evaluate the efficacy and safety of the combination of irinotecan and paclitaxel in patients with advanced stage…”
Get full text

Metastatic myoepithelial carcinoma of the vulva treated with carboplatin and paclitaxel by Noronha, Vanita, Cooper, Dennis L, Higgins, Susan A, Murren, John R, Kluger, Harriet M

Get more information

Modulating multidrug resistance: can we target this therapy? by Murren, John R

Get full text

Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer by Burtness, Barbara, Thomas, Laurie, Sipples, Rebecca, McGurk, Meghan, Salikooti, Saritha, Christoforou, Maryanne, Mirto, Gayle, Salem, Ronald, Sosa, Julieann, Kloss, Robert, Rahman, Zia, Chung, Gina, Lacy, Jill, Murren, John R

“…Docetaxel and irinotecan have activity in pancreatic cancer. The combination of docetaxel and irinotecan is attractive because of preclinical evidence of…”
Get full text

Erlotinib OSI/Roche/Genentech by Kim, Tracy E, Murren, John R

“…Erlotinib (CP-358774, OSI-774, Tarceva), a quinazoline derivative, is an orally active epidermal growth factor receptor tyrosine kinase inhibitor under…”
Get more information

Phase I Dose Escalation Trial of Weekly Docetaxel Plus Irinotecan in Patients with Advanced Cancer by Bleickardt, Eric, Argiris, Athanassios, Rich, Randy, Blum, Kathi, McKeon, Anne, Tara, Harold, Zelterman, Daniel, Burtness, Barbara, Davies, Marianne J., Murren, John R.

“…Background. Docetaxel and irinotecan have additive or synergistic activity in vitro and in vivo as well as differing toxicities and unique mechanisms of…”
Get full text

Therapy for stage IIIB and stage IV non-small cell lung cancer by Kim, Tracy E, Murren, John R

“…The treatment options for unresectable stage III NSCLC include definitive RT, chemotherapy, combined chemoradiotherapy, or supportive care. Compared with…”
Get more information

Camptothecin and taxane regimens for small-cell lung cancer by Kwong, Myron S, Bleickardt, Eric, Murren, John R

“…For more than 2 decades, combination chemotherapy has been the standard treatment for patients with small-cell lung cancer. Despite high initial response rates…”
Get more information

A phase II study of topotecan and cyclophosphamide with G-CSF in patients with advanced small cell lung cancer by Hobdy, Erole M, Kraut, Eric, Masters, Gregory, Blum, Kathleen, McKeon, Anne, Byrd, Boyd, Davies, Marianne, Beaulieu, Nancy, Murren, John R

“…We conducted a multicenter phase II study to evaluate the efficacy and safety of the combination of topotecan and cyclophosphamide for patients with advanced…”
Get full text

A Phase II Study of Topotecan and Cyclophosphamide with G-CSF in Patients with Small Cell Lung Cancer with Poor Prognostic Factors by Hobdy, Erole M., Kraut, Eric, Masters, Gregory, Blum, Kathleen, McKeon, Anne, Byrd, Boyd, Murren, John R.

“…Purpose: We conducted a multicenter phase II study to evaluate the efficacy and safety of the combination of topotecan and cyclophosphamide for patients with…”
Get full text

Phase I Study of Perillyl Alcohol in Patients with Refractory Malignancies by Murren, John R., Pizzorno, Giuseppe, DiStasio, Susan A., McKeon, Anne, Peccerillo, Kathleen, Gollerkari, Ashwin, McMurray, Walter, Burtness, Barbara A., Rutherford, Thomas, Li, Xin, Ho, Peter T. C., Sartorelli, Alan

“…We treated 21 patients in a dose-finding and pharmacokinetic study of the monoterpene perillyl alcohol with the drug given orally in 3 divided doses on a…”
Get full text

Therapy for Stage IIIA, IIIB and IV Non–Small Cell Lung Cancer by Kim, Tracy E, Murren, John R

“…Non–small cell lung cancer (NSCLC) accounts for over 80% of all lung cancers and causes more deaths than breast, prostate, and colorectal carcinomas combined…”
Get full text

Lapatinib ditosylate GlaxoSmithKline by Kim, Tracy E, Murren, John R

“…Lapatinib ditosylate, an ErbB-2 and EGFR dual tyrosine kinase inhibitor, is being developed by GlaxoSmithKline plc for the potential treatment of solid tumors…”
Get more information

Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphoma by ARGIRIS, Athanassios, HEALD, Peter, KUZEL, Timothy, FOSS, Francine M, DISTASIO, Susan, COOPER, Dennis L, ARBUCK, Susan, MURREN, John R

“…To evaluate the role of 9-aminocamptothecin (9-AC), a synthetic camptothecin analog, in advanced cutaneous T-cell lymphoma (CTCL). Eligible patients had stage…”
Get full text

Angiogenesis in non-small cell lung cancer. A new target for therapy by Kim, Tracy E, Murren, John R

“…Non-small cell lung cancer (NSCLC) is cured with surgery in a minority of affected persons. Chemotherapy and radiation can palliate and extend survival of…”
Get more information

P-Glycoprotein Expression and Multidrug Resistance in Cutaneous T-cell Lymphoma by Jillella, Anand P., Murren, John R., Hamid, Khawaja K., Longley, B. Jack, Edelson, Richard L., Cooper, Dennis L.

“…Abstract Advanced-stage cutaneous T-cell lymphoma (CTCL) is generally resistant to standard chemotherapy. Because P-glycoproteiri (P-gp) has beeti detected in…”
Get full text